Sleep

How a Sleeping-Pill Taper Actually Works

Save

Stopping a sleeping pill suddenly tends to backfire — sleep often gets worse before it gets better, and some hypnotics carry real withdrawal risk. This article explains why guidelines recommend a gradual, individualized taper instead, what the FDA's specific safety warnings have to do with that decision, and why pairing the taper with cognitive behavioral therapy for insomnia produces the most durable results.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Why do clinicians recommend tapering instead of stopping suddenly?

Because stopping a regularly used sleeping pill all at once tends to backfire, and because clinical guidelines specifically recommend offering a taper rather than an abrupt stop. Guidelines recommend offering a gradual taper, not an abrupt stop. A 2018 evidence-based deprescribing guideline recommends that clinicians offer to taper benzodiazepines and z-drugs used for insomnia — particularly for adults 65 and older, given the documented harms of continued use — with cognitive behavioral therapy for insomnia (CBT-I) offered as the alternative 1.

Sleeping pill risks in older adults are a large part of why that recommendation exists: falls, fractures, and cognitive effects accumulate with continued use in a way that a single night's dose doesn't reveal. That's also why the guideline frames tapering as something to offer, not something to impose — the decision belongs to the person taking the medication, in conversation with whoever prescribed it.

What actually goes wrong when someone stops abruptly?

Sleep tends to get worse before it gets better — a rebound effect where insomnia symptoms temporarily intensify past their pre-medication baseline — and for some hypnotics, physical dependence means abrupt discontinuation can also trigger anxiety, agitation, or other withdrawal-type symptoms. The evidence report behind the American College of Physicians' insomnia guideline found that these drugs generally produce modest benefits alongside real harm signals, which is part of why an abrupt stop, on top of a drug that was already only modestly helping, tends to feel worse than the problem it was meant to solve 2.

None of this means every taper needs to be slow-motion or drawn out. It means the pace and structure should be decided deliberately, with someone qualified to weigh the specific drug, the length of use, and the person's health history, not worked out from a generic schedule.

Who actually decides the pace and structure of a taper?

The prescribing clinician, working from the specific drug, how long it's been used, and the person's overall health, not a generic timetable. This article deliberately doesn't lay out a week-by-week schedule, because the responsible version of that schedule depends on details a general article can't know: which hypnotic, at what point of use, alongside which other medications or conditions.

What the guidelines do agree on is a hypnotic discontinuation gradual taper principle: reduce gradually rather than stopping outright, especially after weeks or months of regular use, and expect the process to take real time rather than a single decisive night 1. Getting off a sleeping pill safely is a process built around that person's specific situation, worked out with the clinician who can see the whole picture, not a protocol to follow from an article.

What role do FDA's specific safety warnings play here?

They're concrete evidence, not abstract worry. The FDA's 2019 boxed warning is its strongest type of label warning. In April 2019 the FDA added that boxed warning to the prescription drugs actually labeled for insomnia — zolpidem, eszopiclone, and zaleplon — after reports of serious injury and death from sleepwalking, sleep-driving, and other complex behaviors performed with no memory of them afterward 3. In 2013, the FDA separately required lower recommended zolpidem doses after finding that many people still had impairing blood levels the next morning, high enough in some cases to affect driving 4.

Next-day driving impairment is one of the more concrete, checkable reasons someone might raise a taper with their clinician in the first place: it's a safety question with an answer, not a vague sense that a pill isn't good to be on forever. That's exactly when residual sedation risk shows up, which is part of why it's worth naming directly rather than treating hypnotic risk as an abstraction.

Does pairing a taper with CBT-I actually help?

Yes, this is one of the best-supported ideas in the whole taper conversation. In a randomized trial of older adults, cognitive behavioral therapy for insomnia outperformed the z-drug zopiclone on objective sleep-efficiency and slow-wave-sleep measures at both the end of treatment and six months later, while zopiclone alone was no better than placebo by the later follow-up 5. A separate meta-analysis of 20 CBT-I trials found clinically meaningful, durable improvements in how long it takes to fall asleep, how much time is spent awake overnight, and overall sleep efficiency 6.

CBT-I vs sleeping pills isn't really a fair fight once duration is factored in: the medication's benefit tends to fade while CBT-I's tends to hold. Supervised taper behavioral therapy, reducing the medication while a therapist or clinician actively works on the sleep habits and thoughts that were propping up the reliance on it, is the combination the evidence favors over either a taper alone or CBT-I started only after the fact.

What does a realistic timeline feel like, even without a fixed schedule?

It's rarely a straight line. Many people find some nights get harder before they get easier, especially in the first stretch, and the overall process tends to take real time rather than resolving in days, but exactly how long, and in what steps, is a clinical decision, not something a general article can responsibly hand out as a template. Guidelines describe the gradual approach in principle without prescribing a universal timetable, because the safe pace for one person's benzodiazepine use after ten years looks nothing like the safe pace for someone who has taken a z-drug nightly for two months 1.

That variability is the honest answer, even though it's less satisfying than a checklist. Anyone who has been offered a specific plan by a clinician has, in effect, already gotten the individualized version of what this section is describing in general terms.

What's worth bringing to that first conversation?

A short, specific list beats a vague worry. Worth asking: why was this medication started and is that reason still present, what would the taper's general shape look like for this specific drug and history, what symptoms during the process would warrant a call rather than waiting it out, and what's the plan for sleep itself, not just for stopping the pill.

The sleep-medication conversation worth having treats the taper and the sleep problem as two separate things that both need a plan, rather than assuming that stopping the pill alone fixes the insomnia underneath it. Cognitive behavioral therapy for insomnia, started before or during the taper, is generally the answer to that second half.

Common questions

It can be, especially after regular use of benzodiazepines or z-drugs over weeks or months — rebound insomnia, anxiety, and other withdrawal-type symptoms are all possible. That risk is exactly why deprescribing guidelines recommend offering a gradual taper instead of an abrupt stop, worked out with the clinician who prescribed the medication.

There's no single answer, because it depends on which medication, how long it's been used, and the person's health history. General guidelines describe a gradual reduction over real time rather than a fixed number of days, but the specific pace is a decision for the prescribing clinician, not something to plan from an article.

It can, especially if nothing else has changed about the sleep habits and thoughts that were there before the medication started. Pairing a taper with cognitive behavioral therapy for insomnia addresses that directly, and trial evidence suggests it produces more durable results than either the medication or an unsupported taper alone.

It's possible, but it removes the safety check that catches withdrawal symptoms early and adjusts the pace when something isn't working. Guidelines that recommend tapering describe it as something a clinician offers and manages, not a self-directed project, particularly for anyone who has used the medication regularly for weeks or longer.

Older adults carry more of the documented harms from continued hypnotic use — falls, fractures, and cognitive effects — which is a large part of why deprescribing guidelines specifically call out adults 65 and older for a taper conversation. That same increased vulnerability is a reason to involve a clinician closely in the process, not a reason to avoid tapering.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

If things feel heavy, a person is available anytime — call or text 988.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When a taper needs medical attention right away

  • —seizures, hallucinations, or severe confusion after reducing or stopping a benzodiazepine
  • —a racing heartbeat, tremor, or agitation that escalates rather than settles in the days after a dose reduction
  • —thoughts of self-harm appearing or worsening during the process

Seizures, hallucinations, or severe confusion during a taper are a medical emergency — call 911 or go to the nearest emergency room rather than waiting it out. Thoughts of self-harm warrant an immediate call to 988.

This article explains the general principles behind tapering off a sleeping pill; it is not a taper schedule and does not replace an individualized plan from the clinician managing the medication.

References

  1. 1.Pottie K, Thompson W, Davies S, et al. (2018). Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline. Canadian Family Physician. link2018 evidence-based deprescribing guideline recommending clinicians offer to taper benzodiazepines and z-drugs used for insomnia, especially in adults 65+, given harms like falls and cognitive impairment, with CBT-I as the alternative.
  2. 2.Wilt TJ, MacDonald R, Brasure M, et al. (2016). Pharmacologic Treatment of Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians. Annals of Internal Medicine. doi:10.7326/M15-1781ACP evidence review documenting modest, short-term benefit and harm signals across insomnia drugs generally; not a source for specific dosing.
  3. 3.US Food and Drug Administration (2019). Certain Prescription Insomnia Medicines: New Boxed Warning — Due to Risk of Serious Injuries Caused by Sleepwalking, Sleep Driving and Engaging in Other Activities While Not Fully Awake. FDA Drug Safety Communication. link ✓FDA's 2019 boxed warning on complex sleep behaviors for the insomnia-labeled z-drugs zolpidem, eszopiclone, and zaleplon.
  4. 4.US Food and Drug Administration (2013). Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). FDA Drug Safety Communication. link ✓FDA's 2013 finding of next-morning impairment and driving-relevant blood levels leading to lower recommended zolpidem doses.
  5. 5.Sivertsen B, Omvik S, Pallesen S, et al. (2006). Cognitive Behavioral Therapy vs Zopiclone for Treatment of Chronic Primary Insomnia in Older Adults: A Randomized Controlled Trial. JAMA. doi:10.1001/jama.295.24.2851 ✓RCT showing CBT-I outperformed the z-drug zopiclone on objective sleep measures at end of treatment and 6-month follow-up in older adults.
  6. 6.Trauer JM, Qian MY, Doyle JS, Rajaratnam SMW, Cunnington D (2015). Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis. Annals of Internal Medicine. doi:10.7326/M14-2841 ✓Meta-analysis of 20 CBT-I RCTs showing clinically meaningful, durable improvement in sleep-onset latency, wake after sleep onset, and sleep efficiency.

6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library